http://www.pasteur.fr/applications/dri/English/listTechnologies.html
Business Development and Industrial Partnerships Department
List of technologies available for licensing
Last updated: Junuary 2 2002
| D.I. # | Inventor Contact | Title |
| 87.07 | Jean-Michel FOURNIER | Production of capsular polysaccharides characteristic of Staphylococcus aureus using coagulase negative Staphylococci : vaccine and diagnostic applications |
| 91.13 | Gilles MARCHAL | Mycobacterium Proteins and their applications (naxi test) |
| 91.19 | Didier LERECLUS | Replicon of a gram positif bacteria for the construction of recombinant vectors |
| 91.43 | François ROUGEAU | A new antibodies and proteins diversity process |
| 92.22 | Bernard DUJON | I-Sce1 enzyme and its applications |
| 93.40 | Mario TOSI | Procedure for the detection of molecules containing nucleotidic mispairings |
| 94.29 | Véronique VINCENT | Identification of Mycobacterium xenopi |
| 94.32 | Denise PAULIN | Desmine Promotor and its applications for gene therapy |
| 94.52/98.01 | Jean-Pierre CHANGEUX | Transgenic mouse that is defective for the subunit Beta2 nicotinic neuronal receptor: An animal model for screening. |
| 94.61 | Christine PETIT | Genetic diagnostic for deafness and blindness |
| 95.16 | Jean-François NICOLAS | Retro-viral vector for inserting genes in eucaryotic cells |
| 95.33/96.42 | Claude LECLERC | Recombinant parvovirus-like particles for inducing cytotoxic T-cell response: use in antiviral and antitumoral drugs or vaccines |
| 96.02 | Denise PAULIN | Promotor of the SM22 gene and its applications for gene therapy |
| 96.07 | Patrick GRIMONT | Probes for 16 S RNA : detection of E. Coli or Shigella |
| 96.12 | Patrick GRIMONT | Taxotron software for the automatic identification of bacteria |
| 96.29 | Ara HOVANESSIAN | Treatment of HIV infection by targeting a novel receptor |
| 96.31 | Jean-Louis VIRELIZIER | Human SDF chemokine and its application as a HIV therapeutic |
| 96.42/95.33 | Claude LECLERC | Recombinant parvovirus-like particles for inducing cytotoxic T-cell response: use in antiviral and antitumoral drugs or vaccines |
| 96.51 | Christine PETIT | Probe for deafness associated with renal dysfunction |
| 96.53 | Robert LONGIN | MultiMicroFermentors |
| 96.61 | Claude LECLERC | Synthetic compositions of tumor antigen-sugars, and their vaccine applications |
| 96.68 | Christophe d'ENFERT | Strains of pyrG. Aspergillus fumigatus and their application in the screening of antifungals |
| 96.69 | Pierre CHARNEAU | Central DNA Flap Sequence for new Lentiviral Vectors |
| 97.05 | Christine PETIT |
Polynucleotides associated with Branchio-Oto Renal syndrome. Molecular diagnosis of BOR sundrome. |
| 97.07 | Oreste ACUTO | Procedure for screening using ZAP-70 |
| 97.08 | Philippe BRULET | TTC Fragment of the tetanic toxin : a vector for the treatment and the diagnostic of neuronal diseases |
| 97.09 | Brigitte GICQUEL | LHP Protein from Mycobacterium tuberculosis - Applications for vaccines and diagnostic |
| 97.32 | Christine PETIT | Mutated gene for connexine 26 |
| 97.35 | Margaret BUCKINGHAM | Plasmid containing the sequence for the enhancer 3' which is specific for skeletal muscles- Application in gene therapy |
| 97.44 | Stewart COLE | Genomic analysis method for the detection and identification of mycobacteria |
| 98.01/94.52 |
Jean-Pierre CHANGEUX |
Transgenic mice that are defective for the alpha 4 subunit nicotinic neuronal receptor. Animal model for screening. |
| 98.08 | Agnès LABIGNE | UreI protein: a novel target for Helicobacter pylori eradication therapy |
| 98.10 | Claude PARSOT | Screening method for inhibitors and activators of type III secretion system in gram negative bacteria |
| 98.17 | F. ARENZANA-SEISDEDOS | Monoclonal antibodies anti-SDF1 hybridomas |
| 98.20 | Philippe MARLIERE | Procedure for the production in vivo of chemically diversified proteins |
| 98.21 | Brigitte GICQUEL | Procedure for the screening of antibiotic molecules active against Mycobacteria |
| 98.30 | Jean-Luc GUESDON | Molecular diagnostic for prelingual deafness |
| 98.31 | Brigitte GICQUEL | New sequences of M. tuberculosis and the identification of associated genes |
| 98.37 | Noël TORDO | DNA vaccine against lyssavirus infection |
| 98.40 | Jean-Marc CAVAILLON | Hybridoma of anti-IL1 receptor antagonist |
| 98.44 | Anna WEYER | A humanized mast cell system fixing human IgE: Use for screening of immunological and chemical reagents endowed with anaphylactogenic or anti-degranulating properties |
| 98.47 | François LEMONNIER | Utilization of nucleotidic sequences for in vivo melanoma therapy |
| 98.50 | Margaret BUCKINGHAM | New cardiac activation sequence and its application in gene therapy |
| 98.51 | Stewart COLES | Banque génomique de BCG. Applications vaccinale et diagnostique. |
| 98.78 | Jacques THEZE | Peptide p1-30 mimicking some IL-2 effects |
| 99.26 | Michel VERON | New nucleoside derivatives with antiviral and anticarcinogenic properties |
| 99.28 | Paola MINOPRIO | A B-Cell mitogen : A novel approach for vaccination and/or therapy ; the exemple of Trypanosoma cruzi |
| 99.35 | Gérard PERRET | Development of anti-vascular endothelial growth factor receptor peptides as therapeutic and/or imaging agents |
| 99.36/85 | François ROUGEON | Bioactive peptides derived from submandibular rat 1 protein (SMR1) and its derivatives: therapeutic and diagnostic applications. |
| 99.38 | Ralf ALTMEYER | A new method for rapid screening of drugs inhibiting HIV entry |
| 99.44 | Pierre DRUILHE | Mucosal immunization using lipid-tailed peptides without adjuvant |
| 99.53 | Hoang Oanh NGHIEM | Use of thiamine triphosphate to phosphorylate nerve and muscle cells |
| 99.61 | Jean-Pierre CHANGEUX | a CGRP mutant mice. Use for the screening of morphine-type molecules. |
| 99.68/69 | Hugues BEDOUELLE | Novel antibody-based fluorescence biosensor using no additional reagents |
| 99.70 | Francis BIVILLE | Improved large-scale recombinant protein production in bacteria |
| 99.72 | Yves JACOB | Constrained peptides libraries for use in a combinatorial approach to selecting molecules of pharmacological interest |
| 99.75 | Michèle BOULOY | Attenuated Rift Valley Fever Virus: human and veterinary vaccine applications |
| 99.77 | Philip AVNER | X-linked nucleosome assembly protein l-like 2 (Nap1l2) gene: diagnostic and therapeutic applications |
| 99.83 | Paola MINOPRIO | A B-Cell mitogen : A novel approach for vaccination and/or therapy ; the exemple of Trypanosoma cruzi |
| 99.85/36 | François ROUGEON | Bioactive peptides derived from submandibular rat 1 protein (SMR1) and its derivatives: therapeutic and diagnostic applications. |
| 99.86 | Olivier SCHWARTZ | A screening method to identify new HIV inhibitors |
| 99.92 | Adrien SIX | A new software package |
| 00.01 | Franck KUNST | Sequence of Photorhabdus luminescens genome (TT01 strain) |
| 00.03 | Philippe DESPRES | Apoptotic sequence |
| 00.04 | Nicole GUISO-MACLOUF | Antigenic variants of pertactin in Bordetella: diagnostic and immunogenic applications in veterinary field |
| 00.05 | Christophe D'ENFERT | cDNA library from Aspergillus nidulans for cloning of genes by functional complementation in S. cerevisiae yeast |
| 00.10 | Huseyin FIRAT | Hybridomas producing anti-HLA-H antibodies for the diagnosis of human hemachromatosis |
| 00.11 | Alain ISRAËL | Detection of mutations in Nemo gene: use in diagnosis of familial incontinentia pigmenti |
| 00.13 | Isabelle TARDIEUX | Therapeutic use of specific domains of toxofilin, a novel actin-binding protein from Toxoplasma gondii |
| 00.16 | Anne DEJEAN | Identification of hepatocellular carcinoma (HCC) tumor suppressor genes: diagnostic and therapeutic applications |
| 00.18 | Simon WAIN-HOBSON | Live recombinant HIV vaccine |
| 00.19 | Jüng GYSIN | Novel P. falciparum proteins from ring-stage infected erythrocytes: use in the prevention and treatment of malaria |
| 00.20 | Michel Y. POPOFF | A new treatment for preventing salmonellosis in animals |
| 00.21 | Hoang-Oanh NGHIEM | Purification of histidine kinase proteins and their use in phosphorylation of proteins involved in allergy |
| 00.25 | Gilles MARCHAL | Immunogenic glycopeptides derived from Mycobacterium tuberculosis: diagnostic and vaccine applications |
| 00.26 | Agnès LABIGNE | Genomic random library of H. pylori |
| 00.28 | Philippe GLASER | Sequencing of the Listeria monocytogenes genome: therapeutic applications |
| 00.29 | Michel VERON | In vivo and in vitro synthesis of nucleoside triphosphate analogs using mutant nucleoside diphosphate kinase (NDPK) |
| 00.32 | Philippe GLASER | Genomic sequence of Streptococcus agalactiae (Streptococcus B) : Vaccine, therapeutic and diagnostic applications. |
| 00.43 | Bernard DUJON | Novel nucleotide sequences of Saccharomyces cerevisiae and their use in the detection of hemiascomycetous yeasts |
| 00.44 | Bernard DUJON | Microsatellite typing kit for the identification of yeast strains: food testing and human diagnostic applications |
| 00.45 | Bernard DUJON | Specific primers from the Saccharomyces cerevisiae genome for the design of microarrays . |
| 00.48 | Jean-Pierre CHANGEUX | Knockout mice lacking the alpha6 subunit of the neuronal nicotinic acetylcholine receptor (nAChR) and their use in drug screening |
| 00.49 | Jean-Pierre CHANGEUX | Transgenic mice with mutations of the beta2 subunit of the neuronal nicotinic acetylcholine receptor (nAChR) |
| 00.50 | Gabriel GACHELIN | Methods of screening for potential anti-atherosclerosis agents |
| 00.54 | Edouard YERAMIAN | Computational method for enhanced detection of genes and coding regions within long genomic sequences |
| 00.57 | Françoise BALEUX | Synthesis of Doxorubicin-peptide conjugates |
| 00.59 | Claude LECLERC | B. pertussis adenylate cyclase-activating peptide receptor and its use in screening for immunologically/pharmacologically active molecules |
| 00.65 | Françoise DROMER | Cryptococcus neoformans protein Pep1p : diagnostic, prognostic and therapeutic applications |
| 00.69 | Alice DAUTRY-VARSAT | Methods for prevention or treatment of Chlamydia infection |
| 00.72 | Stewart COLE | Identification of novel targets for the diagnosis, prevention and/or treatment of mycobacterial infections |
| 00.75 | Suzanne CHANTEAU | Simple and rapid diagnosis of human plague |
| 00.80 | Hechmi LOUZIR |
Vaccine against leishmaniasis using virulence antigen P55 gene
|
| 00.81 | Marc DELARUE | Crystal structure of M. tuberculosis TMP kinase: application to the rational design of TMP kinase inhibitors and the development of novel antibiotics |
| 01.01 | Pierre BEGUIN | Gordonia terrae genes involved in the biodegradation of gasoline oxygenates ethyl t-butyl ether (ETBE), methyl t-butyl ether (MTBE) and t-amyl methyl ether (TAME) |
| 01.05 | Penelope MAVROMARA | Compositions and methods for the identification of viral inhibitors of host cell protein synthesis shut-off |
| 01.06 | Bernardo B. VARGAFTIG | Partial identification of molecules which act against tuberculin allergy after BCG vaccination |
| 01.07 | Jacques Thèze | Peptide p1-30 mimicking some IL-2 effects |
| 01.11 | Jürg GYSIN | Method of screening conformational antigens using monoclonal antibodies. |
| 01.17 | Philippe DESPRES | Molecular determinants specific for West Nile virus clone IS-98-STI allowing identification of cellular genes involved in host response to flaviviral and related viral infections |
| 01.18/01.19 | Jean-Louis GUENET | Novel congenic strain of mice carrying a wild type chromosomal fragment conferring resistance to Flaviviridae. Vaccine and therapeutic application. |
| 01.20 | James DI SANTO | Novel strain of alymphoid mice for xenotransplantation |
| 01.22 | Marie-Louise GOUGEON | Novel cytofluorometric method for quantitation and characterization of cell-mediated cytotoxic activity |
| 01.23 | Jean-Michel FOURNIER | Novel vaccine composition inducing protective antibodies against cholera |
| 01.24 | Hélène MUNIER-LEHMANN | M. tuberculosis thymidylate kinase (TMPK) inhibitors: use in the development of new antitubercular drugs |
| 01.25 | Nicolas R. ESCRIOU | Recombinant influenza virus for the expression of heterologous proteins in mammalian cells useful in vaccine and therapeutic applications |
| 01.30 | Nicolas R. ESCRIOU | Generation of defective recombinant RNA replicons. Use for vaccination and therapy in humans and animals |
| 01.31 | Pierre DRUILHE | Identification of two novel Plasmodium falciparum antigens involved in host response to the pre-erythrocyte stages of the parasite |
| 01.34 | Octavian BARZU | Genes encoding UMP kinase in bacteria, methods for purifying UMP kinase and use of UMP kinase in compound screening |
| 01.43 | Lionel FRANGEUL | GMP-Tool-Box: a software package for bacterial genome sequencing projects from shotgun follow-up to annotation |
| 01.45 | Farid CHETOUANI | Find Target: a software tool for subtractive genome analysis |
Other technology briefs
are in the process of being written and will be soon available.
Contact
The list above is not comprehensive; therefore, for more information or other enquiries, please contact:
Office of Technology Transfer
(33) 1 40 61 36 95
(33) 1 40 61 37 32
valor@pasteur.fr
ALL INFORMATION, DATA, AND
MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION
PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS
OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR
LEGAL ADVICE. THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND
COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH
YOUR HEALTH CARE PROVIDER.